<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Denileukin diftitox (ONTAK) is indicated for the treatment of patients with cutaneous T cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical experience with this drug in other <z:hpo ids='HP_0002665'>lymphomas</z:hpo> is limited </plain></SENT>
<SENT sid="2" pm="."><plain>This case report concern a patient with stage IV follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> who, relapsing after autologous transplant and having failed multiply systemic therapies, including retuximab and CHOP, achieved a prolonged remission with denileukin diftitox </plain></SENT>
</text></document>